Ventripoint Diagnostics CEO: “We’re at the Tipping Point”

Share on Linkedin

Ventripoint Diagnostics Ltd. (TSXV: VPT) CEO discusses the government approval and financing to sell its heart diagnostic tool


SmallCapPower spoke with Ventripoint Diagnostics Ltd. (TSXV: VPT) President and CEO Dr. George Adams at the recent F1 Capital Conference in Montreal, where he talked about Ventripoint’s plans to combat heart disease through its new diagnostic tool. Find out more about their goals for global growth by watching this short video.

Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: